account_circleRecruiting
Advanced non-small cell lung cancer, Cancer
Bayer Identifier:
22913
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Expanded access to provide BAY2927088 for the treatment of locally advanced or metastatic NSCLC with HER2 mutation
Trial purpose
The purpose of this Expanded Access Program (EAP) is to allow patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with mutations in the human epidermal growth factor receptor 2 (HER2) gene, which have no other therapeutic option, to receive BAY2927088.
Key Participants Requirements
Sex
AllAge
18 YearsTrial summary
Enrollment Goal
N/ATrial Dates
null - TodayPhase
N/ACould I Receive a placebo
NoProducts
BAY2927088Accepts Healthy Volunteer
N/ATrial design
Trial Type
Expanded AccessIntervention Type
DrugTrial Purpose
TreatmentAllocation
N/ABlinding
N/AAssignment
N/ATrial Arms
N/A